Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-04-10 |
2024-02 |
-0.8 |
-0.76 |
0.04 |
5.00% |
2024-02-15 |
2023-11 |
-0.51 |
N/A |
N/A |
N/A |
2024-02-15 |
2023-11 |
-0.51 |
-0.77 |
-0.26 |
-50.98% |
2023-10-12 |
2023-08 |
-0.69 |
-0.68 |
0.01 |
1.45% |
2023-10-12 |
2023-08 |
-0.69 |
N/A |
N/A |
N/A |
2023-07-13 |
2023-05 |
-0.63 |
N/A |
N/A |
N/A |
Date |
Firm |
Action |
From |
To |
2023-10-12 |
RBC Capital |
Upgrade |
Outperform |
Outperform |
2023-10-12 |
Needham |
Upgrade |
Buy |
Buy |
2023-09-07 |
HC Wainwright & Co. |
Upgrade |
Buy |
Buy |
2023-09-06 |
Needham |
Upgrade |
Buy |
Buy |
2023-07-23 |
HC Wainwright & Co. |
Upgrade |
Buy |
Buy |
2023-07-16 |
Morgan Stanley |
Upgrade |
Equal-Weight |
Equal-Weight |
Date |
Name |
Relation |
Quantity |
Description |
2021-08-09 |
BEAURANG PIERRE |
Officer |
121.00K |
Sale |
2020-07-27 |
COLUMN GROUP L.P. |
Beneficial Owner of more than 10% of a Class of Security |
0.00 |
Conversion of Exercise of derivative security |
2024-04-29 |
HANSEN GWENN |
Officer |
39.60K |
Sale |
2020-07-27 |
REDMILE GROUP, L.L.C. |
Beneficial Owner of more than 10% of a Class of Security |
0.00 |
Conversion of Exercise of derivative security |
2024-04-29 |
RING CHRISTINE |
Officer |
19.84K |
Sale |
2020-07-27 |
THIRD ROCK VENTURES III, L.P. |
Beneficial Owner of more than 10% of a Class of Security |
0.00 |
Conversion of Exercise of derivative security |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Blackrock Inc. |
4.52M |
45.15M |
9.32% |
2023-06-29 |
Baker Brothers Advisors, LLC |
3.88M |
38.78M |
8.00% |
2023-06-29 |
Wasatch Advisors LP |
3.87M |
38.66M |
7.98% |
2023-06-29 |
Deep Track Capital, Lp |
3.00M |
29.95M |
6.18% |
2023-06-29 |
Redmile Group, LLC |
2.86M |
28.54M |
5.89% |
2023-06-29 |
Vanguard Group Inc |
2.69M |
26.89M |
5.55% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-09-29 |
ARK ETF Tr-ARK Genomic Revolution ETF |
2.57M |
20.20M |
5.30% |
2023-06-29 |
Vanguard Total Stock Market Index Fund |
1.57M |
15.70M |
3.24% |
2023-06-29 |
Price (T.Rowe) New Horizons Fund |
1.33M |
13.26M |
2.74% |
2023-08-30 |
iShares Russell 2000 ETF |
1.07M |
9.11M |
2.21% |
2023-08-30 |
SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF |
964.11K |
8.19M |
1.99% |
2023-06-29 |
Wasatch Small Cap Growth Fund |
921.26K |
9.20M |
1.90% |